Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Mar 1;28(2):e626-e628.
doi: 10.1097/RHU.0000000000001767.

Combination Therapy With Tofacitinib and IL-12/23, IL-23, or IL-17A Inhibition for the Treatment of Refractory Psoriatic Arthritis: A Case Series

Megan Shurey  1 , Ashley Yip  1 , Olga Ziouzina  2 , Jonathan Chan  3 , Jan P Dutz
Affiliations
Case Reports

Combination Therapy With Tofacitinib and IL-12/23, IL-23, or IL-17A Inhibition for the Treatment of Refractory Psoriatic Arthritis: A Case Series

Megan Shurey et al. J Clin Rheumatol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

A.Y. and M.S. have no conflicts of interest or competing interests; J.C. has advised, received honoraria, or received research funding from AbbVie, Amgen, Celgene, Eli Lilly, Gilead, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, and UCB; J.D. has advised, received honoraria or research funding from AbbVie, Amgen, Bausch, Celgene, Leo Pharma, Janssen, Novartis, Sanofi, and UCB. O.Z. has advised, received honoraria or research funding from Amgen, AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, Sandoz, and UCB.

References

    1. Singh AJ, Guyatt G, Ogdie A, et al. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol . 2019;71:5–32.
    1. Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis . 2020;79:700–712.
    1. Möttönen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet . 1999;353:1568–1573.
    1. Metyas S, Tomassian C, Messiah R, et al. Combination therapy of apremilast and biologic agent as a safe option of psoriatic arthritis and psoriasis. Curr Rheumatol Rev . 2019;15:234–237.
    1. Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol . 2011;186:4234–4243.

Publication types

MeSH terms

LinkOut - more resources